Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: A phase II study of the Gruppo Oncologico dell' Italia meridionale (prot 2106)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 581-585

  Giuliani, Francesco ^a   Molica, Stefano ^b   Maiello, Evaristo ^a   Battaglia, C ^b   Gebbia, Vittorio ^c   Di Bisceglie, Maurizio ^a   Vinciarelli, Gianluca ^a   Gebbia, Nicola ^d   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c LA MADDALENA CANCER CENTER   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

CPT 11; Gastric cancer; Metastases; Mitomycin C

Indexed keywords

IRINOTECAN; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; FEMALE; FEVER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; ITALY; LIFE TABLES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN; NEUTROPENIA; PERITONEAL NEOPLASMS; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 29044446486     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000190398.52142.7f     Document Type: Article

References (31)

1. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587-691.
2. Glimelius B, Ekstrom K, Hoffmann K, et al. Randomised comparison between chemotherapy versus plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-168.
3. Murad AM, Santiago FF, Petroianu A. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
4. Hill ME, Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev. 1998;24:113-118.
5. Kelsen DP, Van-De Velde CJH, Minsky BD. Gastric cancer: clinical management. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, eds. Gastrointestinal Oncology Principles and Practice. Philadelphia: Lippincott; 2002:383-422.
6. Hsiang YH, Lihou MG, Liu LF, et al. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complex as a mechanism of cell killing by camptothecine. Cancer Res. 1989;49:5077-5082.
7. Bissery MC, Vrignau P, Lavelle F, et al. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996;7:437-460.
8. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer. 1999;35:371-379.
9. Futatsuki K, Wakui A, Nakoa I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother. 1994;21:1033-1038.
10. Dorr RT. New findings in the pharmacokinetic, metabolic and drug-resistance aspects of mitomycin-c. Sem Oncol. 1988;15:32-41.
11. Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer. 1975;3:675-682.
12. Verweij J, van den Burg ME, Pinedo HM. Mitomycin C-induced hemolitic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol. 1987;8:33-41.
13. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture, Int J Cancer. 1992;50:604-610.
14. Yamao T, Shirao K, Matsumura Y, et al. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol. 2001;12:1729-1735.
15. Gil Delgado MA, Antoine EC, Guinet F, et al. Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am J Clin Oncol. 2001;24:251-254.
16. Bamias A, Papamichael D, Syrigos K, et al. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. J Chemother. 2003;15:275-281.
17. Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9:307-310.
18. Stathopoulos GP, Rigatos SK, Fountzilas G, et al. Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. Oncol Rep. 2002;9:89-92.
19. Sulkes A, Smith J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer. 1994;70:380-383.
20. Einzig AL, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol. 1996;13:87-93.
21. Taguchi T. A late phase II study of docetaxel in patients with gastric cancer. Proc Asco. 1997;16:934. [abstr.]
22. Vanhoefer U, Wilke H, Harstrick A, et al. Phase II study of docetaxel as second-line chemotherapy in metastatic gastric cancer. Proc Asco. 1999;18:1163.[abstr.]
23. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol. 2000;23:341-344.
24. Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol. 2000;11:1263-1266.
25. Bang YJ, Kang YK, Kang YK, et al. Docetaxel 75 mg/mq is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol. 2002;32:248-254.
26. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale. Anticancer Res. 2003;23:4219-4222.
27. Andre' T, Louvet C, Ychou M, et al. Docetaxel-epirubicin as second line treatment for patients with advanced gastric cancer. Proc Asco. 1999;18:1062. [abstr.]
28. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. JCO. 1997;15:921-927.
29. Boku N, Ohtsu A, Shimada H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. JCO. 1999;17:319-323.
30. Grau JJ, Martin M, Gascon P, et al. Phase II study of irinotecan (CPT-11) and mitomycin C (MMC) combination in patients with advanced gastric cancer (ENG). Preliminary results. Proc Asco. 2001;20:2284.[abstr.]
31. Gold PJ, Carter G, Livingston R, et al. Phase II trial of irinotecan (CPT-11) and mitomycin C (MMC) in the treatment of metastatic esophageal and gastric cancers. Proc Asco. 2001;20;644. [abstr.]